{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:59Z","timestamp":1788153539572,"version":"build-2803163510"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Squamous cell carcinoma of the prostate (SCCP) is a rare subtype of prostate cancer with a poor prognosis, and no consensus exists regarding the treatment of SCCP. Nectin-4, a cell adhesion molecule predominantly expressed in a wide variety of cancers, emerged as a promising therapeutic target due to its over expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 69-year-old male patient received transurethral resection of the prostate for lower urinary tract symptoms (LUTS) and was diagnosed with prostatic acinar adenocarcinoma. Androgen deprivation therapy (ADT) was administered, and 22 months later, the patient presented with LUTS again, and radical prostatectomy (RP) was performed; subsequent pathologic examination revealed mixed prostatic carcinoma, with the squamous and glandular components accounting for 70% and 30%, respectively. Immunohistochemical (IHC) staining of the mixed carcinoma tissue from the RP specimen demonstrated strong immunoreactivity for Nectin-4 exclusively in the squamous component, not the glandular component. A retrospective assay of seven additional SCCP specimens from our center showed the same result. In the current case, although apalutamide, a novel androgen receptor inhibitor, in combination with ADT and pelvic radiotherapy was administered 1 month postoperatively, the patient experienced both biochemical and radiographic progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first report of a case of hormonal therapy-induced SCCP, in which Nectin-4 was expressed exclusively in the squamous component, not the glandular component. Nectin-4 might be a therapeutic target for SCCP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1914312","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:43Z","timestamp":1788150583000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Expression of nectin-4 in squamous cell carcinoma of prostate: a pilot study and case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Xizhen","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Urology, Zhongnan Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zhongnan Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiantao","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhongnan Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhongnan Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhongnan Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhongnan Hospital of Wuhan University","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.11.020","article-title":"Squamous transformation of prostate adenocarcinoma: A report of two cases with genomic profiling","volume":"18","author":"Dizman","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.humpath.2023.10.003","article-title":"Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma","volume":"142","author":"Tekin","year":"2023","journal-title":"Hum Pathol"},{"key":"B4","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Cold","year":"2026","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.62347\/zqci9925","article-title":"Post-therapeutic squamous cell transformation of a metastatic prostate adenocarcinoma with comparison of molecular profiles: A case report and review of the literature","volume":"17","author":"Li","year":"2024","journal-title":"Int J Clin Exp Pathol"},{"key":"B7","first-page":"56","article-title":"Squamous cell carcinoma of the prostate","volume":"13","author":"Malik","year":"2011","journal-title":"Rev Urol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.22541\/au.171119460.03017818\/v1","article-title":"Demographics, histopathology, and treatment outcomes of squamous cell carcinoma of the prostate","volume":"7","author":"Gordon","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-026-04495-1","article-title":"Nectin-4 expression in vulvar squamous cell carcinoma","author":"Stuebs","year":"2026","journal-title":"Virchows Arch"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.3390\/cancers17213410","article-title":"Tissue factor expression in penile squamous cell carcinoma: A potential marker of HPV-independent disease","volume":"17","author":"Jackson","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251361877","article-title":"Expression patterns of TROP2 and nectin-4 in oropharyngeal squamous cell carcinoma in relation to HPV status: Potential biomarkers for targeted therapy","volume":"17","author":"Klasen","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1159\/000545141","article-title":"Clinical response to enfortumab vedotin and pembrolizumab in a patient with vaginal squamous cell carcinoma: A case report","volume":"18","author":"Glover","year":"2025","journal-title":"Case Rep Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.18572","article-title":"Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer","volume":"28","author":"Weiten","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24846","article-title":"Nectin-4 expression in prostatic adenocarcinoma: An immunohistochemical study","volume":"85","author":"Baraban","year":"2025","journal-title":"Prostate"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1158\/1538-7445.AM2024-4632","article-title":"Abstract 4632: Lineage plasticity as a determinant of antibody-drug conjugate target expression in urothelial bladder cancer","volume":"84","author":"Luo","year":"2024","journal-title":"Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1914312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:44Z","timestamp":1788150584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1914312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":15,"alternative-id":["10.3389\/fonc.2026.1914312"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1914312","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1914312"}}